可溶性内皮细胞蛋白C受体和可溶性血栓调节蛋白在2型糖尿病诊疗中的临床意义  

Soluble endothelial protein C receptor and soluble thrombomodulin in patients with type 2 diabetes mellitus

作　　者：钱定良[1] 闫绍荣 刘凌云[1] QIAN Dingliang;YAN Shaorong;LIU Lingyun(Department of Clinical Laboratory,Ruian People's Hospital,Ruian 325200,Zhejiang,China)

机构地区：[1]瑞安市人民医院检验科,浙江瑞安325200

出　　处：《检验医学》2017年第3期208-209,共2页Laboratory Medicine

摘　　要：目的探讨血管内皮损伤在2型糖尿病(DM)患者微血管并发症发生、发展中的临床意义。方法采用酶联免疫吸附试验(ELISA)测定150例2型DM患者和150名体检正常者(正常对照组)血浆可溶性内皮细胞蛋白C受体(sEPCR)和可溶性血栓调节蛋白(sTM)水平。结果与正常对照组相比,DM患者血浆sEPCR和s TM水平均显著升高(P<0.05)。结论血浆sEPCR和sTM水平升高与DM患者血管病变的发生和严重程度密切相关,是反映血管内皮细胞功能的良好指标。Objective To investigate the role of vascular endothelial injury in the development of microvascular complications in type 2 diabetes mellitus(DM)patients. Methods Enzyme-linked immunosorbent assay(ELISA) was used to determine for soluble endothelial protein C receptor(sEPCR) and soluble thrombomodulin(sTM) levels in 150 type 2 DM patients and 150 healthy subjects(healthy control group). Results Compared with healthy control group,the levels of sEPCR and sTM in DM patients increased(P<0.05). Conclusions The levels of sEPCR and sTM have correlations with the occurrence and severity of vessel diseases in DM patients,which can be biomarkers for evaluating endothelial function.

关 键 词：可溶性内皮细胞蛋白C受体 可溶性血栓调节蛋白 2型糖尿病 

分 类 号：R446.1[医药卫生—诊断学]